Paper76797
Mechanism of the antipsychotic effect in the treatment of acute schizophrenia.
Johnstone EC and 4 others. Lancet, 1978. Cited by 377 papers, by iCite.
Cite this record
ConductScience Library. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Papers, record 76797. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/76797
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Flupenthixol | Major topic |
| Schizophrenia | Major topic |
| Thioxanthenes | Major topic |
| Acute Disease | |
| Adolescent | |
| Adult | |
| Chlorpromazine | |
| Clinical Trials as Topic | |
| Drug Evaluation | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Isomerism | |
| Male | |
| Placebos | |
| Receptors, Dopamine | |
| Research Design |
Source PubMed
Cited by77
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 377 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40109883 | Seminal Contributions of Timothy J. Crow. | Psychol Med | 2025 | https://conductscience.org/library/papers/40109883 | PubMed |
| 38172494 | Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia. | Schizophrenia (Heidelb) | 2024 | https://conductscience.org/library/papers/38172494 | PubMed |
| 37196827 | Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia. | Behav Brain Res | 2023 | https://conductscience.org/library/papers/37196827 | PubMed |
| 36880665 | Consciousness, (meta)cognition, and culture. | Q J Exp Psychol (Hove) | 2023 | https://conductscience.org/library/papers/36880665 | PubMed |
| 36700319 | Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia. | Clin Psychopharmacol Neurosci | 2023 | https://conductscience.org/library/papers/36700319 | PubMed |
| 35894865 | Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial. | Int J Neuropsychopharmacol | 2022 | https://conductscience.org/library/papers/35894865 | PubMed |
| 34518523 | Differential dopamine release by psychosis-generating and non-psychosis-generating addictive substances in the nucleus accumbens and dorsomedial striatum. | Transl Psychiatry | 2021 | https://conductscience.org/library/papers/34518523 | PubMed |
| 33340975 | Motor-related oscillatory activity in schizophrenia according to phase of illness and clinical symptom severity. | Neuroimage Clin | 2021 | https://conductscience.org/library/papers/33340975 | PubMed |
| 32803162 | Quantifying the Core Deficit in Classical Schizophrenia. | Schizophr Bull Open | 2020 | https://conductscience.org/library/papers/32803162 | PubMed |
| 32166169 | The development of antipsychotic drugs. | Brain Neurosci Adv | 2018 | https://conductscience.org/library/papers/32166169 | PubMed |
| 31434513 | The Core Deficit of Classical Schizophrenia: Implications for Predicting the Functional Outcome of Psychotic Illness and Developing Effective Treatments. | Can J Psychiatry | 2019 | https://conductscience.org/library/papers/31434513 | PubMed |
| 31214054 | Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. | Front Psychiatry | 2019 | https://conductscience.org/library/papers/31214054 | PubMed |
| 30758785 | Dopamine in psychiatry: a historical perspective. | J Neural Transm (Vienna) | 2019 | https://conductscience.org/library/papers/30758785 | PubMed |
| 30038229 | A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. | Mol Psychiatry | 2020 | https://conductscience.org/library/papers/30038229 | PubMed |
| 29213544 | Clozapine for severe ("kraepelinian") schizophrenia: Sustained improvement over 5 years. | Dement Neuropsychol | 2008 | https://conductscience.org/library/papers/29213544 | PubMed |
| 25184047 | Recent advances in understanding schizophrenia. | F1000Prime Rep | 2014 | https://conductscience.org/library/papers/25184047 | PubMed |
| 25177834 | Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/25177834 | PubMed |
| 24915451 | Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/24915451 | PubMed |
| 24560140 | Implications of cellular models of dopamine neurons for schizophrenia. | Prog Mol Biol Transl Sci | 2014 | https://conductscience.org/library/papers/24560140 | PubMed |
| 24395698 | Chlorpromazine versus placebo for schizophrenia. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/24395698 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/76797
GET https://conductscience.org/api/papers/v1/76797/cited_by?page=2